Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 12 pages · English
Syntara Limited (ASX: SNT), a clinical-stage drug development company, is pleased to provide a summary of its activities for the quarter ended 31 December 2025: • Lead asset amsulostat continues to build momentum o Amsulostat clinical and preclinical data presented at American Society of Hematology (ASH) Annual Meeting in Orlando o Second myelodysplastic syndrome (MDS) study initiated with launch
Story so far
Earlier from Syntara
- Amsulostat and Garvan in MRFF funded pancreatic trial
- SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited
- Skin scarring program to progress on positive Phase1a result
- Quarterly Shareholder Report and Appendix 4C
- Positive top-line Phase 2a data confirms competitive profile
Later from Syntara
- Half Year Report and Appendix 4D
- Positive FDA feedback for Amsulostat P2b trial
- Continuation of trading halt
- $8m placement and share purchase plan
- Share Purchase Plan Offer Booklet
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara